Welcome to our dedicated page for Nasus Pharma Ltd. SEC filings (Ticker: NSRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Nasus Pharma Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Nasus Pharma Ltd.'s regulatory disclosures and financial reporting.
Nasus Pharma Ltd. (NSRX) announced that it has appointed Eyal Rubin as its new Chief Financial Officer and Executive Vice President, effective November 19, 2025. The company entered into an Employment Agreement with him on the same date and expects to provide its standard indemnification agreement, similar to those for other directors and executive officers. The company states that there are no related party transactions involving Mr. Rubin that require disclosure. Mr. Rubin brings extensive experience from prior CFO roles at Protalix BioTherapeutics and BrainStorm Cell Therapeutics, and treasury leadership roles at Teva Pharmaceutical Industries. Nasus Pharma also issued a press release on November 20, 2025 announcing his appointment.
Nasus Pharma Ltd. reported that it has begun a Phase 2 clinical study of its product candidate NS002, with the first participant already dosed. This step marks a move into a more advanced stage of human testing, where the company will further evaluate NS002’s performance and safety in patients. The update was provided through a press release dated November 18, 2025, which is attached to this report as an exhibit.
Nasus Pharma Ltd (NSRX): Schedule 13G filed — Dr. Ronnie Hershman reported beneficial ownership of 1,383,512 ordinary shares, representing 15.3% of the class. The filing attributes 891,187 shares to Hershman Holdings LLC (managed by Dr. Hershman) with sole voting and dispositive power; 429,307 shares are held by Phoenix Solutions Ltd., where he may be deemed to share voting and investment power; and 63,018 shares are issuable upon exercise of options exercisable within 60 days.
For Hershman Holdings LLC alone, the filing shows 891,187 shares (9.9%) with sole voting and dispositive power. The percentages are based on 9,014,105 ordinary shares outstanding as of September 30, 2025.
Nasus Pharma Ltd. (NSRX) reported a significant shareholder on Schedule 13G. Dr. Dalia Megiddo beneficially owns 1,888,873 ordinary shares, representing 20.9% of the class. She holds sole voting and sole dispositive power over all reported shares.
The percentage is based on 9,014,105 ordinary shares outstanding as of September 30, 2025, as advised to the reporting person. The filing relates to ordinary shares (CUSIP M7071P109).
Nasus Pharma Ltd. (NSRX): Udi Gilboa filed a Schedule 13G reporting beneficial ownership of 1,901,311 ordinary shares, representing 21.1% of the class. He holds sole voting and sole dispositive power over all reported shares, with no shared voting or dispositive power.
The percentage is based on 9,014,105 ordinary shares outstanding as of September 30, 2025, as advised to the reporting person. The filing relates to Ordinary Shares (CUSIP M7071P109), and identifies Gilboa as a citizen of Israel.
Nasus Pharma Ltd. filed a Form 6-K noting that on November 3, 2025, it made an updated corporate presentation available on its website. The presentation is furnished as Exhibit 99.1.
The company states the presentation is not a prospectus or offering document and does not constitute an invitation or offer to sell or solicit the purchase of any securities.
Capital Point Ltd. reported ownership of 575,129 ordinary shares of Nasus Pharma Ltd., representing 6.35% of the outstanding class based on 9,059,635 shares. The filing shows Capital Point has sole voting and dispositive power over those shares and indicates the holdings were not acquired to change or influence control of the issuer. The report identifies the filer as an Israel-organized entity and provides principal office addresses for both the issuer and filer. The statement is a Schedule 13G disclosure of beneficial ownership and does not include transactions, financial results, or forward-looking commentary.
FAQ
What is the current stock price of Nasus Pharma Ltd. (NSRX)?
What is the market cap of Nasus Pharma Ltd. (NSRX)?
